Detalhe da pesquisa
1.
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Acta Neuropathol
; 147(1): 85, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38758238
2.
Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma.
Pituitary
; 26(4): 482-487, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37428397
3.
The treatment of aggressive prolactinomas with everolimus.
Pituitary
; 26(4): 474-481, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37428396
4.
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
J Neurooncol
; 146(1): 163-170, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31823165
5.
Neurologic Emergencies in the Patients With Cancer.
J Intensive Care Med
; 32(2): 99-115, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26704760
6.
Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
J Neurooncol
; 130(3): 529-533, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27704386
7.
Leptomeningeal disease in histone-mutant gliomas.
Neurooncol Adv
; 5(1): vdad068, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37346983
8.
Integration of an enhanced recovery after surgery program for patients undergoing pituitary surgery.
World J Otorhinolaryngol Head Neck Surg
; 8(4): 330-338, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36474665
9.
Combination Olaparib and Temozolomide for the Treatment of Glioma: A Retrospective Case Series.
Neurology
; 2022 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35948444
10.
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.
Neurosurgery
; 91(2): e51-e56, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35544035
11.
Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma.
J Endocr Soc
; 5(10): bvab133, 2021 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34466766
12.
Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
J Clin Endocrinol Metab
; 105(12)2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32930787
13.
Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
Brain Pathol
; 30(3): 653-660, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984581
14.
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
Acta Neuropathol Commun
; 8(1): 186, 2020 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33168106
15.
Clinical Outcomes of Recurrent Intracranial Meningiomas Treated with Proton Beam Reirradiation.
Int J Part Ther
; 5(4): 11-22, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31773037
16.
Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?
J Endocr Soc
; 3(9): 1693-1706, 2019 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31528829
17.
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.
Clin Cancer Res
; 25(18): 5537-5547, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31263031
18.
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
J Clin Endocrinol Metab
; 103(10): 3925-3930, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30085142
19.
Is there a role for early chemotherapy in the management of pituitary adenomas?
Neuro Oncol
; 18(10): 1350-6, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27106409
20.
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
Neuro Oncol
; 16(1): 123-30, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24285548